Literature DB >> 7998639

The types of drugs used by HIV-infected injection drug users in a multistate surveillance project: implications for intervention.

T Diaz1, S Y Chu, R H Byers, B S Hersh, L Conti, C A Rietmeijer, E Mokotoff, S A Fann, D Boyd, L Iglesias.   

Abstract

OBJECTIVES: This study sought to describe the drugs used by drug injectors infected with human immunodeficiency virus (HIV) and to determine factors associated with the primary injection drug used.
METHODS: A cross-section of persons 18 years of age or older reported with HIV or acquired immunodeficiency syndrome (AIDS) to local health departments in 11 US states and cities was surveyed.
RESULTS: Of 4162 persons interviewed, 1147 (28%) reported ever having injected drugs. Of these 1147 injectors, 72% primarily injected a drug other than heroin. However, the types of drugs injected varied notably by place of residence. Heroin was the most commonly injected drug in Detroit (94%) and Connecticut (48%); cocaine was the most common in South Carolina (64%), Atlanta (56%), Delaware (55%), Denver (46%), and Arizona (44%); speedball was most common in Florida (46%); and amphetamines were most common in Washington (56%). Other determinants of the type of drug primarily injected were often similar by region of residence, except for heroin use. Polysubstance abuse was common; 75% injected more than one type of drug, and 85% reported noninjected drug use.
CONCLUSIONS: Preventing the further spread of HIV will require more drug abuse treatment programs that go beyond methadone, address polysubstance abuse, and adapt to local correlates of the primary drug used.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7998639      PMCID: PMC1615366          DOI: 10.2105/ajph.84.12.1971

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  13 in total

1.  Trends of HIV-1 risk reduction among initiates into intravenous drug use 1982-1987.

Authors:  D Vlahov; J C Anthony; D Celentano; L Solomon; N Chowdhury
Journal:  Am J Drug Alcohol Abuse       Date:  1991       Impact factor: 3.829

2.  Cocaine use and HIV infection in intravenous drug users in San Francisco.

Authors:  R E Chaisson; P Bacchetti; D Osmond; B Brodie; M A Sande; A R Moss
Journal:  JAMA       Date:  1989-01-27       Impact factor: 56.272

3.  Epidemiology of drug abuse: an overview.

Authors:  N J Kozel; E H Adams
Journal:  Science       Date:  1986-11-21       Impact factor: 47.728

4.  Follow-up evaluation of treatment of drug abuse during 1969 to 1972.

Authors:  D D Simpson; L J Savage; M R Lloyd
Journal:  Arch Gen Psychiatry       Date:  1979-07

5.  Health insurance coverage among persons with AIDS: results from a multistate surveillance project.

Authors:  T Diaz; S Y Chu; L Conti; B L Nahlen; B Whyte; E Mokotoff; A Shields; P J Checko; M Herr; Q Mukhtar
Journal:  Am J Public Health       Date:  1994-06       Impact factor: 9.308

6.  Demographic characteristics, drug use, and sexual behavior of i.v. drug user with AIDS in Bronx, New York.

Authors:  L Schrager; G Friedland; C Feiner; P Kahl
Journal:  Public Health Rep       Date:  1991 Jan-Feb       Impact factor: 2.792

7.  Risk factors for human immunodeficiency virus infection in intravenous drug users.

Authors:  E E Schoenbaum; D Hartel; P A Selwyn; R S Klein; K Davenny; M Rogers; C Feiner; G Friedland
Journal:  N Engl J Med       Date:  1989-09-28       Impact factor: 91.245

Review 8.  Methadone treatment and acquired immunodeficiency syndrome.

Authors:  J R Cooper
Journal:  JAMA       Date:  1989 Sep 22-29       Impact factor: 56.272

9.  Risk factors for infection with human immunodeficiency virus among intravenous drug abusers in New York City.

Authors:  M Marmor; D C Des Jarlais; H Cohen; S R Friedman; S T Beatrice; N Dubin; W el-Sadr; D Mildvan; S Yancovitz; U Mathur
Journal:  AIDS       Date:  1987-05       Impact factor: 4.177

View more
  9 in total

1.  Large decline in injecting drug use in Amsterdam, 1986-1998: explanatory mechanisms and determinants of injecting transitions.

Authors:  E J van Ameijden; R A Coutinho
Journal:  J Epidemiol Community Health       Date:  2001-05       Impact factor: 3.710

2.  Injection drug use among stimulant users in a national sample.

Authors:  Li-Tzy Wu; Daniel J Pilowsky; Wendee M Wechsberg; William E Schlenger
Journal:  Am J Drug Alcohol Abuse       Date:  2004       Impact factor: 3.829

3.  Frontline Science: Buprenorphine decreases CCL2-mediated migration of CD14+ CD16+ monocytes.

Authors:  Matias Jaureguiberry-Bravo; Lillie Lopez; Joan W Berman
Journal:  J Leukoc Biol       Date:  2018-05-23       Impact factor: 4.962

4.  Impact of HIV and a history of marijuana dependence on procedural learning among individuals with a history of substance dependence.

Authors:  Raul Gonzalez; Randi M Schuster; Jasmin Vassileva; Eileen M Martin
Journal:  J Clin Exp Neuropsychol       Date:  2011-06-24       Impact factor: 2.475

5.  The supplement to HIV-AIDS Surveillance project: an approach for monitoring HIV risk behaviors.

Authors:  J W Buehler; T Diaz; B S Hersh; S Y Chu
Journal:  Public Health Rep       Date:  1996       Impact factor: 2.792

6.  Methadone treatment protects against HIV infection: two decades of experience in the Bronx, New York City.

Authors:  D M Hartel; E E Schoenbaum
Journal:  Public Health Rep       Date:  1998-06       Impact factor: 2.792

7.  Heroin and cocaine co-use in a group of injection drug users in Montréal.

Authors:  Francesco Leri; Jane Stewart; Annie Tremblay; Julie Bruneau
Journal:  J Psychiatry Neurosci       Date:  2004-01       Impact factor: 6.186

Review 8.  Opioids and Opioid Maintenance Therapies: Their Impact on Monocyte-Mediated HIV Neuropathogenesis.

Authors:  Matias Jaureguiberry-Bravo; Rebecca Wilson; Loreto Carvallo; Joan W Berman
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

9.  Correlates of illicit methadone use in New York City: a cross-sectional study.

Authors:  Danielle C Ompad; Crystal M Fuller; Christina A Chan; Victoria Frye; David Vlahov; Sandro Galea
Journal:  BMC Public Health       Date:  2008-10-28       Impact factor: 3.295

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.